CN113747914A - 抑制表达asph的肿瘤生长和进展 - Google Patents

抑制表达asph的肿瘤生长和进展 Download PDF

Info

Publication number
CN113747914A
CN113747914A CN201980091889.XA CN201980091889A CN113747914A CN 113747914 A CN113747914 A CN 113747914A CN 201980091889 A CN201980091889 A CN 201980091889A CN 113747914 A CN113747914 A CN 113747914A
Authority
CN
China
Prior art keywords
asph
composition
tumor
purified
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980091889.XA
Other languages
English (en)
Chinese (zh)
Inventor
J·R·万兹
X·董
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rhode Island Hospital
Original Assignee
Rhode Island Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhode Island Hospital filed Critical Rhode Island Hospital
Publication of CN113747914A publication Critical patent/CN113747914A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/844—Liver
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
CN201980091889.XA 2018-12-13 2019-12-13 抑制表达asph的肿瘤生长和进展 Pending CN113747914A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862779422P 2018-12-13 2018-12-13
US62/779,422 2018-12-13
PCT/US2019/066174 WO2020123912A1 (en) 2018-12-13 2019-12-13 Inhibition of asph expressing tumor growth and progression

Publications (1)

Publication Number Publication Date
CN113747914A true CN113747914A (zh) 2021-12-03

Family

ID=71077044

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980091889.XA Pending CN113747914A (zh) 2018-12-13 2019-12-13 抑制表达asph的肿瘤生长和进展

Country Status (7)

Country Link
US (1) US20220054614A1 (https=)
EP (1) EP3893925A4 (https=)
JP (1) JP2022512384A (https=)
KR (1) KR20210129634A (https=)
CN (1) CN113747914A (https=)
CA (1) CA3123006A1 (https=)
WO (1) WO2020123912A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
WO2020223639A1 (en) * 2019-05-01 2020-11-05 Sensei Biotherapeutics, Inc. Combination therapies for cancer
CR20220220A (es) 2019-11-18 2022-09-20 Janssen Biotech Inc Vacunas basadas en calr y jak2 mutantes y sus usos
EP4175664A2 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102596234A (zh) * 2009-07-24 2012-07-18 罗得岛医院 针对表达天冬酰胺酰-β-羟化酶的肿瘤的树突细胞疫苗
US20150202291A1 (en) * 2013-11-05 2015-07-23 Cognate Bioservices, Inc. Combinations of checkpoint inhibitors and therapeutics to treat cancer
US20150306198A1 (en) * 2014-04-24 2015-10-29 Rhode Island Hospital Aspartate-ß-hydroxylase Induces Epitope-specific T Cell Responses in Tumors
CN107001414A (zh) * 2014-12-23 2017-08-01 伊玛提克斯生物技术有限公司 用于肝细胞癌(hcc)和其他癌症免疫治疗的新型肽和肽组合物
US20180162943A1 (en) * 2015-06-05 2018-06-14 H. Lee Moffitt Cancer Center And Research Institute, Inc. Gm-csf/cd40l vaccine and checkpoint inhibitor combination therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140271689A1 (en) * 2013-03-15 2014-09-18 Panacea Pharmaceuticals Therapeutic Cancer Vaccine Targeted to HAAH (Aspartyl-[Asparaginyl]-beta-Hydroxylase)
JP2019513373A (ja) * 2016-03-31 2019-05-30 ネオン セラピューティクス， インコーポレイテッド ネオ抗原およびその使用方法
WO2019217913A1 (en) * 2018-05-10 2019-11-14 Sensei Biotherapeutics, Inc. Aspartate beta-hydroxylase chimeric antigen receptors and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102596234A (zh) * 2009-07-24 2012-07-18 罗得岛医院 针对表达天冬酰胺酰-β-羟化酶的肿瘤的树突细胞疫苗
US20150202291A1 (en) * 2013-11-05 2015-07-23 Cognate Bioservices, Inc. Combinations of checkpoint inhibitors and therapeutics to treat cancer
US20150306198A1 (en) * 2014-04-24 2015-10-29 Rhode Island Hospital Aspartate-ß-hydroxylase Induces Epitope-specific T Cell Responses in Tumors
CN107001414A (zh) * 2014-12-23 2017-08-01 伊玛提克斯生物技术有限公司 用于肝细胞癌(hcc)和其他癌症免疫治疗的新型肽和肽组合物
US20180162943A1 (en) * 2015-06-05 2018-06-14 H. Lee Moffitt Cancer Center And Research Institute, Inc. Gm-csf/cd40l vaccine and checkpoint inhibitor combination therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YOSHIFUMI IWAGAMI等: "Lambda phage-based vaccine induces antitumor immunity in hepatocellular carcinoma", 《HELIYON》, vol. 3, no. 9, pages 1 - 24 *

Also Published As

Publication number Publication date
US20220054614A1 (en) 2022-02-24
KR20210129634A (ko) 2021-10-28
CA3123006A1 (en) 2020-06-18
JP2022512384A (ja) 2022-02-03
EP3893925A4 (en) 2023-01-18
WO2020123912A1 (en) 2020-06-18
EP3893925A1 (en) 2021-10-20

Similar Documents

Publication Publication Date Title
JP6656349B2 (ja) 単純ヘルペスウイルスおよび免疫チェックポイント阻害薬を使用して、メラノーマを治療するための方法
CN113747914A (zh) 抑制表达asph的肿瘤生长和进展
KR102873947B1 (ko) 수지상 세포 면역요법
JP2026015423A (ja) ＩＦＮ－γの抗腫瘍補助薬の調製への応用
EP2895170A1 (en) Inhibition of viral infection-triggered asthma with c-kit inhibitor
CA2768398C (en) Dendritic cell vaccines for asparaginyl-.beta.-hydroxylase expressing tumors
Lin et al. Evaluating the cellular targets of anti-4-1BB agonist antibody during immunotherapy of a pre-established tumor in mice
WO2023055885A2 (en) Ezh2 inhibition in pancreatic cancer
Garrido et al. Vaccination against nonmutated neoantigens induced in recurrent and future tumors
US20220175816A1 (en) Aim2 inhibitors and uses thereof
HK40065126A (en) Inhibition of asph expressing tumor growth and progression
CN114788864A (zh) Ldlr在肿瘤免疫治疗、增强免疫细胞免疫效应中的应用
US20250009823A1 (en) Oncolytic virus regimens for the treatment of cancer
Alam et al. Development of a novel modified vaccine (TheraVacM) for curative treatment of mouse solid tumors
JP2020515618A (ja) ベータカテニン発現を減少させて免疫療法を強化する
TW201124159A (en) Small interference RNA molecule and applications thereof
Ausejo-Mauleón TIM-3 blockade as a therapeutic approach for diffuse intrinsic pontine glioma
HK40081211A (en) A method for treating melanoma using a herpes simplex virus and an immune checkpoint inhibitor
US20110229496A1 (en) Method for regulating survival and memory of t helper 1 cells
HK1255016A1 (en) Methods of treating solid or lymphatic tumors by combination therapy
JP2013053114A (ja) 肝癌、肝芽腫及び膵癌の治療剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40065126

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20211203